The rare and orphan disease market exhibits a number of unique characteristics that make goal setting incredibly challenging. In this blog post, we explore one proven goal setting methodology with a track record of improving goal accuracy and equity for rare disease products.

The prescribing behavior exhibited by HCPs and the loyalty they have to the products they prescribe are two critical elements that inform how biopharma sales representatives sell to HCPs. In this blog post, we explore whether an HCP is more likely to switch product loyalty or behavioral segment, and what the implications of this answer are for your sales strategy.

Too often, biopharma sales compensation plans that do not have a fixed budget, such as goal or commission, end up paying or more or less than expected. In this blog post, we explore an invaluable tool called a budget risk analysis that helps companies anticipate how much their plan will pay out before implementation.

The various frameworks under which a commission-based sales compensation plan can be designed offer biopharma companies great flexibility in tailoring a plan to the unique needs of their particular sales force and product portfolio. In this blog post, we explore the three major commission frameworks and when you should use each.

Critical to the productivity and efficiency of your sales force is ensuring the optimal targets are being identified and assigned the proper call frequency. In this blog post, we explore how to determine the accuracy of your biopharma targets.

One of the critical components to maximizing a sales force’s productivity and efficiency is call planning. In this blog post, we explore why sales representatives don’t always follow call plans and why this may be beneficial for a company’s bottom line.

Let’s examine some of the key attributes that can be used to determine the productivity and efficiency of sales calls made to targets, which we’ve not only summarized into an easy to remember acronym—GAPPS®—but also developed into a statistically-based diagnostic tool.

While sales compensation design for any product launch can be incredibly challenging, it is especially complex for products that treat rare and orphan diseases. In this blog post, we explore three sales compensation pitfalls to avoid for the launch of a rare disease product.

The easiest way of targeting HCPs is to pursue those who are prescribing in high volume in the therapeutic class. However, seldom is the easy way also the best way to target HCPs. Let’s explore why and how HCPs should be targeted in order to drive sales and adoption.

There are a number of ways biopharma companies collect sales compensation plan feedback from the field. In this blog post, we explore some of the methods commonly used, the best method to utilize, and how this method can be effectively employed.

Although the forced rank sales compensation plan is one of the most popular designs utilized for a biopharma product launch, the launch stage is actually the stage in which forced rank does the most harm. In this blog post, we explore why you should avoid forced rank sales compensation plans for a product launch.

When designed properly, contests are an excellent supplement to the sales compensation plan to create excitement and attention around a particular product and activity. In this blog post, we discuss the do’s and don’t of biopharma contest design.

Though large volume territories contribute so much to a biopharma company’s bottom line, many goal-based sales compensation plans actually unexpectedly penalize large volume territories. In this blog post, we explore how this inequity occurs and what you can do about it.

In this blog post, we explore four common indicators that a sales compensation plan is leaving sales on the table and should be changed.

Critical to the success of a multi-product bag is ensuring that all products get sufficient attention without taking focus away from the product(s) deemed most important. However, there are number of sales compensation pitfalls that make achieving this very challenging. In this blog post, we outline what they are and how to navigate them.

The two most common sales compensation plan periods adopted in biopharma—quarter and trimester—each have their own set of advantages and disadvantages as well as circumstances for use. In this blog post, we explore the pros and cons of these two plan period types.